Silver
| Address | 14, Wiryeseong-daero, Songpa-gu, Seoul, Republic of Korea | ||
|---|---|---|---|
| Telephone | +82-2-410-9114 | Fax | +82-2-410-9159 |
| Website | www.hanmi.co.kr | jaehwan.kim@hanmi.co.kr | |
Hanmi jumps up to be a global leading pharmaceutical company with development of new biologics, new chemical entities, and innovative new drugs. The slogan of Hanmi is 'creation and challenge' as Hanmi tries to make new ways for the domestic pharmaceutical market. We have started a distribution revolution with RFID technology,the nation's very first success of US expansion with IMD, and R&D collaboration with global companies.
The eflapegrastim(active ingredient of Rolontis) molecule (72 kDa) consists of an rhG-CSF analog and a recombinant human immunoglobulin (Ig)G Fc fragment conjugatedat their N-termini via a short (3.4k Da) polyethylene glycol linker. The strategy of adding an Fc fragment to extend drug half-life has been used in marketed biologics safely and effectively administered to hundreds of thousands of patients (e.g., etanercept, aflibercept, dulaglutide). Rolontis shows the expected decreased clearance due to its size as well as increased uptake to the bone marrow, presumably due to the interaction of its Fc fragment with Fc receptors on the endothelial surface. The resulting increased potency, as demonstrated by pharmacokinetic and pharmacodynamic data from preclinical and clinical trials, gives rolontis the potential to provide improved risk reduction in the clinic.
